CORT News

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure

Pomerantz LLP Shares Class Action Details With Shareholders in Corcept Therapeutics Incorporated – CORT

Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated and Encourages Investors to Contact the Firm

Corcept präsentiert vollständige Daten aus der zulassungsrelevanten ROSELLA-Studie im Rahmen einer Late-Breaker-Präsentation auf der SGO-Konferenz, begleitet von einer gleichzeitigen Veröffentlichung in The Lancet: Lifyorli™ (Relacorilant) Plus...

Corcept présente les données complètes de l'essai pivot ROSELLA dans le cadre d'une présentation de dernière minute au congrès de la SGO, avec une publication simultanée dans The Lancet : Lifyorli™ (rélacorilant) plus nab-paclitaxel améliore la…

Corcept presenta en el Congreso de la SGO los resultados completos del ensayo clínico ROSELLA, publicados simultáneamente en The Lancet: Lifyorli™ (relacorilant) en combinación con nab-paclitaxel prolonga la supervivencia de pacientes con cáncer...

Corcept presenteert volledige gegevens van het cruciale ROSELLA-onderzoek tijdens de SGO late-breaker sessie, met gelijktijdige publicatie in The Lancet: Lifyorli™ (relacorilant) in combinatie met nab-paclitaxel verbetert de totale overleving bij...

Corcept presenta i dati completi dello studio clinico di fase III ROSELLA nelle notizie dell'ultima ora dell'SGO con la pubblicazione simultanea in The Lancet: Lifyorli™ (relacorilant) in combinazione con nab-paclitaxel migliora la sopravvivenza...